T1	Participants 55 107	type 2 diabetic patients under good glycemic control
T2	Participants 592 710	Thirty-eight patients were randomly assigned to receive nateglinide (270 mg/dL) and 40 to control group (no treatment)
T3	Participants 535 590	type 2 diabetic patients whose HbA1c was less than 6.5%
